Alterations in Levels of CD28-/CD8+ Suppressor Cell Precursor and CD45RO+/CD4+ Memory T Lymphocytes in the Peripheral Blood of Multiple Sclerosis Patients

Overview

Journal Clin Diagn Lab Immunol

Publisher American Society for Microbiology

Specialty Allergy & Immunology

Date 1995 Mar 1

PMID 7697540

Citations 25

Authors

B Crucian

P Dunne

H Friedman

R Ragsdale

S Pross

R Widen

Affiliations

Soon will be listed here.

Abstract

A comprehensive peripheral blood immunophenotype analysis of 16 multiple sclerosis (MS) patients was performed by three-color flow cytometric analysis, and the results were compared with those for age-matched healthy controls. The cell subsets quantified included T cells (CD3+), B cells (CD19+), NK cells (CD56+), CD4+ and CD8+ T cells, cytotoxic (CD28+) and suppressor precursor (CD28-) CD8+ T cells, CD45RA+ and CD45RO+ T cells (CD4+ and CD8+), and CD5+ T and B cells. Analysis of MS patients' peripheral blood revealed essentially normal levels of total T, B, and NK cells. In agreement with results obtained by other investigators, it was found that MS patients had an increased CD4/CD8 ratio, primarily due to a decrease in CD8+ T cells. MS patients were found to have a significantly decreased level of suppressor precursor (CD28-) CD8+ T cells compared with that of controls but to have normal levels of cytotoxic (CD28+) CD8+ T cells. These data indicate that MS patients do not have a general decrease in CD8+ T cells but that they have a specific decrease in the suppressor precursor subset only and normal levels of cytotoxic CD8+ T cells. MS patients also had a significant increase in memory (CD45RO+) CD4+ T cells and displayed a trend towards a decrease in naive (CD45RA+) T cells in the peripheral blood.

Citing Articles

Increased Percentage of CD8CD28 Regulatory T Cells With Fingolimod Therapy in Multiple Sclerosis.

Houston T, Howlett-Prieto Q, Regenauer C, Testai F, Yao F, Feng X Neurol Neuroimmunol Neuroinflamm. 2022; 10(2).

PMID: 36535763 PMC: 9764330. DOI: 10.1212/NXI.0000000000200075.

Immune function in X-linked retinoschisis subjects in an AAV8-RS1 phase I/IIa gene therapy trial.

Mishra A, Vijayasarathy C, Cukras C, Wiley H, Sen H, Zeng Y Mol Ther. 2021; 29(6):2030-2040.

PMID: 33601057 PMC: 8178519. DOI: 10.1016/j.ymthe.2021.02.013.

Re-balance of memory T cell subsets in peripheral blood from patients with CML after TKI treatment.

Yao D, Xu L, Tan J, Zhang Y, Lu S, Li M Oncotarget. 2017; 8(47):81852-81859.

PMID: 29137227 PMC: 5669853. DOI: 10.18632/oncotarget.20965.

CD28 and CD28CD8 Regulatory T Cells: Of Mice and Men.

Vuddamalay Y, van Meerwijk J Front Immunol. 2017; 8:31.

PMID: 28167946 PMC: 5256148. DOI: 10.3389/fimmu.2017.00031.

Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod.

Song Z, Yamasaki R, Kawano Y, Sato S, Masaki K, Yoshimura S PLoS One. 2015; 10(4):e0124923.

PMID: 25919001 PMC: 4412716. DOI: 10.1371/journal.pone.0124923.

References

Reinherz E, Weiner H, Hauser S, Cohen J, Distaso J, Schlossman S . Loss of suppressor T cells in active multiple sclerosis. Analysis with monoclonal antibodies. N Engl J Med. 1980; 303(3):125-9. DOI: 10.1056/NEJM198007173030303. View

Schumacher G, BEEBE G, KIBLER R, Kurland L, Kurtzke J, McDowell F . PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS. Ann N Y Acad Sci. 1965; 122:552-68. DOI: 10.1111/j.1749-6632.1965.tb20235.x. View

Kurtzke J . Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983; 33(11):1444-52. DOI: 10.1212/wnl.33.11.1444. View

Rodeck U, Kuwert E, Scharafinski H, Lehmann H . T lymphocyte populations in multiple sclerosis. Eur Arch Psychiatry Neurol Sci. 1985; 235(2):119-21. DOI: 10.1007/BF00633483. View

Hauser S, Bhan A, Gilles F, Kemp M, Kerr C, Weiner H . Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions. Ann Neurol. 1986; 19(6):578-87. DOI: 10.1002/ana.410190610. View

Morimoto C, Hafler D, Weiner H, Letvin N, Hagan M, Daley J . Selective loss of the suppressor-inducer T-cell subset in progressive multiple sclerosis. Analysis with anti-2H4 monoclonal antibody. N Engl J Med. 1987; 316(2):67-72. DOI: 10.1056/NEJM198701083160202. View

Morimoto C, Steinberg A, Letvin N, Hagan M, Takeuchi T, Daley J . A defect of immunoregulatory T cell subsets in systemic lupus erythematosus patients demonstrated with anti-2H4 antibody. J Clin Invest. 1987; 79(3):762-8. PMC: 424193. DOI: 10.1172/JCI112882. View

Chofflon M, Weiner H, Morimoto C, Hafler D . Loss of functional suppression is linked to decreases in circulating suppressor inducer (CD4+ 2H4+) T cells in multiple sclerosis. Ann Neurol. 1988; 24(2):185-91. DOI: 10.1002/ana.410240203. View

Rose L, Ginsberg A, Rothstein T, Ledbetter J, Clark E . Fluctuations of CD4+ T-cell subsets in remitting-relapsing multiple sclerosis. Ann Neurol. 1988; 24(2):192-9. DOI: 10.1002/ana.410240204. View

10.

Trotter J, Clifford D, McInnis J, Griffeth R, Bruns K, Perlmutter M . Correlation of immunological studies and disease progression in chronic progressive multiple sclerosis. Ann Neurol. 1989; 25(2):172-8. DOI: 10.1002/ana.410250211. View

11.

Hafler D, Weiner H . MS: a CNS and systemic autoimmune disease. Immunol Today. 1989; 10(3):104-7. DOI: 10.1016/0167-5699(89)90236-3. View

12.

Kolmel H, Sudau C . Cell count and ratio of helper/inducer to suppressor/cytotoxic T-cells in the cerebrospinal fluid of patients with multiple sclerosis. J Neurol. 1989; 236(7):424-6. DOI: 10.1007/BF00314904. View

13.

Koide J, Engleman E . Differences in surface phenotype and mechanism of action between alloantigen-specific CD8+ cytotoxic and suppressor T cell clones. J Immunol. 1990; 144(1):32-40. View

14.

Zaffaroni M, Rossini S, Palma R, Ghezzi A, MARFORIO S, CAZZULLO C . Loss of suppressor-inducer T-cells in chronic-progressive multiple sclerosis: preliminary results. Adv Exp Med Biol. 1989; 257:293-5. DOI: 10.1007/978-1-4684-5712-4_32. View

15.

Silverman E, Somma C, Khan M, Melmon K, Engleman E . Abnormal T suppressor cell function in juvenile rheumatoid arthritis. Arthritis Rheum. 1990; 33(2):205-11. DOI: 10.1002/art.1780330208. View

16.

Zaffaroni M, Rossini S, Ghezzi A, PARMA R, CAZZULLO C . Decrease of CD4+CD45+ T-cells in chronic-progressive multiple sclerosis. J Neurol. 1990; 237(1):1-4. DOI: 10.1007/BF00319659. View

17.

Rohowsky-Kochan C, Eiman D, Troiano R, Bansil S, Oleske J, Denny T . Decreased suppressor-inducer T lymphocytes in multiple sclerosis and other neurological diseases. J Neuroimmunol. 1990; 28(2):161-6. DOI: 10.1016/0165-5728(90)90030-q. View

18.

Li S, Ottenhoff T, van den Elsen P, Koning F, Zhang L, Mak T . Human suppressor T cell clones lack CD28. Eur J Immunol. 1990; 20(6):1281-8. DOI: 10.1002/eji.1830200613. View

19.

Gambi D, Porrini A, Giampietro A, Macor S . CD21+ (B2 antigen+) cell decrement and CD4+CD29+ (helper-inducer) cell increment suggest an activation of cell immune reactivity in multiple sclerosis. J Neuroimmunol. 1991; 33(2):97-102. DOI: 10.1016/0165-5728(91)90053-a. View

20.

Freedman M, Ruijs T, Blain M, Antel J . Phenotypic and functional characteristics of activated CD8+ cells: a CD11b-CD28- subset mediates noncytolytic functional suppression. Clin Immunol Immunopathol. 1991; 60(2):254-67. DOI: 10.1016/0090-1229(91)90068-l. View